Puma Biotechnology (PBYI) Common Equity (2010 - 2026)

Puma Biotechnology's Common Equity history runs 17 years deep, the most recent figure standing at $128.4 million for Q1 2026.

• Quarterly Common Equity rose 32.24% year-over-year to $128.4 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $128.4 million (up 32.24% YoY) and the FY2025 annual result came in at $130.3 million, up 41.48% from the prior year.
• Common Equity was $128.4 million for Q1 2026 at Puma Biotechnology, down from $130.3 million in the prior quarter.
• Across five years, Common Equity topped out at $130.3 million in Q4 2025 and bottomed at $7.1 million in Q1 2022.
• A 5-year average of $62.2 million and a median of $51.0 million in 2024 frame the typical range for Common Equity.
• Peak annual rise in Common Equity reached 983.4% in 2022, while the deepest fall reached 56.26% in 2022.
• Puma Biotechnology's Common Equity stood at $21.6 million in 2022, then surged by 147.33% to $53.4 million in 2023, then surged by 72.38% to $92.1 million in 2024, then surged by 41.48% to $130.3 million in 2025, then fell by 1.48% to $128.4 million in 2026.
• Business Quant data shows PBYI's Common Equity at $128.4 million in Q1 2026, $130.3 million in Q4 2025, and $115.3 million in Q3 2025.